Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders (2013 - 2026)

Xenon Pharmaceuticals (XENE) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$102.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 57.27% year-over-year to -$102.3 million; the TTM figure through Mar 2026 stood at -$392.5 million (down 56.11% YoY), while the FY2025 annual figure was -$355.3 million, down 51.61% from the prior year.
• Net Income towards Common Stockholders improved to -$102.3 million in Q1 2026 per XENE's latest filing, from -$114.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$19.4 million in Q1 2022 and bottomed at -$114.6 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$58.8 million across 5 years, with a median of -$48.5 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 146.3% — and 2024, when it decreased 14.87%.
• Xenon Pharmaceuticals' Net Income towards Common Stockholders stood at -$37.4 million in 2022, then decreased by 19.7% to -$44.7 million in 2023, then tumbled by 46.81% to -$65.7 million in 2024, then slumped by 74.51% to -$114.6 million in 2025, then grew by 10.75% to -$102.3 million in 2026.
• Business Quant data shows XENE's Net Income towards Common Stockholders at -$102.3 million in Q1 2026, -$114.6 million in Q4 2025, and -$90.9 million in Q3 2025.